Chardan Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Chardan Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday, March 18th.

Coya Therapeutics Price Performance

Shares of COYA stock opened at $6.68 on Thursday. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.24. The firm has a market capitalization of $111.72 million, a P/E ratio of -10.28 and a beta of 0.31. The company’s fifty day moving average price is $6.33 and its two-hundred day moving average price is $6.49.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.10 million. On average, sell-side analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently modified their holdings of the business. DME Capital Management LP grew its position in shares of Coya Therapeutics by 29.2% during the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock valued at $9,434,000 after buying an additional 372,414 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Coya Therapeutics in the fourth quarter valued at approximately $74,000. Northern Trust Corp increased its stake in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after acquiring an additional 4,777 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Coya Therapeutics during the fourth quarter valued at approximately $59,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.